

Behavioral Characterization of the PS19 Mouse Model of Alzheimer's Disease

Roland Rabl, Livia Breznik, Aaron Woblistin, Tobias Pendl, Magdalena Daurer, Stefanie Flunkert and Manuela Prokesch
QPS Austria, Parkring 12, 8074 Grambach, Austria



BACKGROUND


Tau is a microtubule-associated protein and a primary component of neurofibrillary tangles – one of the major pathological hallmarks of Alzheimer's disease. PS19 transgenic mice overexpressing the disease-associated P301S tau mutation, are shown to present strong tauopathy-related brain pathologies. The aim of this study was to characterize the PS19 mice behaviorally and electromyographically for their cognitive and motor deficits, activity, and compound muscle action potential (CMAP), that can be successfully employed to test novel drug agents and therapeutic treatments.

MATERIAL & METHODS


For this study, 80 PS19 mice of mixed sex and 80 wild type (WT) littermates at the age of 2 to 6 months were included in a cross-sectional experiment. Animals at the age of 2 to 4 months were evaluated in a behavioral test battery for cognitive deficits including the Y-maze, Morris water maze and fear conditioning test. Activity and motor deficits were evaluated in the open field and wire hanging test. Additionally, electromyography (EMG) was performed to measure CMAP. Behavioral tests using 6 months old animals are still in progress.

RESULTS


Cognitive Deficits – Morris Water Maze




No significant differences were detected in the contextual fear conditioning and Y-maze test of 2 and 4 months old PS19 mice (data not shown).



Motor Deficits



Activity – Open Field



CONCLUSION

Our results show that the PS19 mice already start to show cognitive deficits at 4 months of age in the absence of motor deficits or emotional disturbances. Additionally, with a more detailed analysis of strategy learning patterns, we were able to establish a sensitive tool to detect changes in spatial learning. Analysis of 6 months old animals are currently ongoing to complete the characterization of this valuable model to evaluate new compounds against Alzheimer's disease.

Meet QPS at our Booth #17

For more information about the models please visit: www.qpsneuro.com
or send us an e-mail: office-austria@qps.com